PubHawk
July 2025 PMID 39701142

Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo-controlled trial.

Nadine Ezard, Brendan Clifford, Krista J Siefried, Robert Ali, Adrian Dunlop, Rebecca McKetin, Raimondo Bruno, Andrew Carr, James Ward, Michael Farrell, Robert Graham, Paul Haber, Dan Lubman, Mark W Donoghoe, Nick Olsen

Full text PDF Download social card

Mentions

20
Peak: 2 in Jan 2025
across 5 sources since Jan 2025

Extended reach

5,758
potential audience

Total likes

8

Video views

32

Mentions per month

Jan 2025 – Aug 2025

Where it's discussed

  • News9 articles
  • X / Twitter5 posts
  • YouTube2 videos
  • Reddit2 posts
  • Blogs2 articles

AI synopsis

What people are saying

The discussions highlight the mixed results of the study, with comments like 'weak evidence' and comparisons to existing treatments, indicating a cautious curiosity. The tone ranges from analytical to skeptical, especially when mentioning prior attempts and drug options like buprenorphine, emphasizing a nuanced view of the study's significance.

AgreementModerate agreement

Most discussions acknowledge the trial's findings, noting the limited but positive effects of lisdexamfetamine on methamphetamine use.

InterestModerate interest

The posts show moderate interest, with some reflecting on previous research and the potential for future developments.

EngagementNeutral engagement

While some comments reference specific details of the study and related medications, overall engagement remains surface-level.

ImpactModerate impact

The posts suggest the article might influence ongoing research and debate about addiction treatments, though its practical impact is viewed as modest.

Abstract in brief

  • The study was a randomized, double-blind, placebo-controlled trial conducted in Australia to evaluate the safety and effectiveness of a 12-week course of lisdexamfetamine for reducing methamphetamine use in adults.
  • While there was only weak evidence of a significant reduction in methamphetamine use at 13 weeks, participants receiving lisdexamfetamine showed a greater overall reduction in methamphetamine use throughout the entire treatment phase and reported higher satisfaction with the treatment.
  • The trial highlighted that although some benefits were observed, especially in overall use reduction and treatment satisfaction, the primary outcome at 13 weeks showed only minimal statistical significance.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Alan Stacey
@AlanVRK · X

@SchoolBondOtter @wokbonds @elonmusk I see. Is it working? https://t.co/hYk7s9LUcl

Jul 7, 2025 · 3 likes · 4,101 followers View post →
P
@psychopharmacol · X

RCT: Lisdexamfetamine (up to 250 mg/d) appears to reduce methamphetamine days of use over a 12-week treatment period (MD=8.8; 2.7–15.0). The LDX group reported greater self-reported treatment effectiveness (OR= 2.89; 1.67–5.02) and satisfaction https://t.co/spm5nrurct https://t.co/bIaIlMhfk1

Jan 4, 2025 · 3 likes · 1 share · 574 followers View post →
P
@psychopharmacol · X

snmall RCT: Lisdexamfetamine appears to reduce methamphetamine use over a 12-week treatment period (MD=8.8; 2.7–15.0), although there is only weak evidence that reduced use is maintained during the last 4 weeks. AEs with lisdexamfetamine included nausea https://t.co/spm5nrtTmV https://t.co/S6uLWRrqjf

Jun 5, 2025 · 574 followers View post →
Christopher Rodgman, MD
@RodgmanPsych · X

The lab at Baylor where I did my fellowship already tried this for #methamphetamine dependence, with poor results like these. Until a partial agonist like #Buprenorphine is developed to address meth use disorder, we’re left with weak medication options. https://t.co/pFdrHJQAPS

Jan 13, 2025 · 344 followers View post →

All mentions

Alan Stacey
@AlanVRK · X

@SchoolBondOtter @wokbonds @elonmusk I see. Is it working? https://t.co/hYk7s9LUcl

Jul 7, 2025 · 3 likes · 4,101 followers View post →
P
@psychopharmacol · X

snmall RCT: Lisdexamfetamine appears to reduce methamphetamine use over a 12-week treatment period (MD=8.8; 2.7–15.0), although there is only weak evidence that reduced use is maintained during the last 4 weeks. AEs with lisdexamfetamine included nausea https://t.co/spm5nrtTmV https://t.co/S6uLWRrqjf

Jun 5, 2025 · 574 followers View post →
Stats Central
@StatsCentralAus · X

Nadine Ezard and her collaborators, which included Nick and Stats Central alumni Mark Donoghoe, conducted a placebo-controlled trial on the efficacy and safety of lisdexamphetamine in reducing methamphetamine use in people dependent on it. [1/2] https://t.co/4fpGmLuZq5

Feb 11, 2025 · 132 followers View post →
Christopher Rodgman, MD
@RodgmanPsych · X

The lab at Baylor where I did my fellowship already tried this for #methamphetamine dependence, with poor results like these. Until a partial agonist like #Buprenorphine is developed to address meth use disorder, we’re left with weak medication options. https://t.co/pFdrHJQAPS

Jan 13, 2025 · 344 followers View post →
P
@psychopharmacol · X

RCT: Lisdexamfetamine (up to 250 mg/d) appears to reduce methamphetamine days of use over a 12-week treatment period (MD=8.8; 2.7–15.0). The LDX group reported greater self-reported treatment effectiveness (OR= 2.89; 1.67–5.02) and satisfaction https://t.co/spm5nrurct https://t.co/bIaIlMhfk1

Jan 4, 2025 · 3 likes · 1 share · 574 followers View post →